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Abstract
The success of small-diameter tissue engineered vascular grafts (TEVGs) greatly relies on an
appropriate cell source and an efficient cellular delivery and carrier system. Pericytes have
recently been shown to express mesenchymal stem cell features. Their relative availability and
multipotentiality make them a promising candidate for TEVG applications. The objective of this
study was to incorporate pericytes into a biodegradable scaffold rapidly, densely and efficiently,
and to assess the efficacy of the pericyte-seeded scaffold in vivo. Bi-layered elastomeric
poly(ester-urethane)urea scaffolds (length=10mm; inner diameter=1.3mm) were bulk seeded with
3×106 pericytes using a customized rotational vacuum seeding device in less than 2 min (seeding
efficiency > 90%). The seeded scaffolds were cultured in spinner flasks for 2 days and then
implanted into Lewis rats as aortic interposition grafts for 8 weeks. Results showed pericytes
populated the porous layer of the scaffolds evenly and maintained their original phenotype after
the dynamic culture. After implantation, pericyte-seeded TEVGs showed a significant higher
patency rate than the unseeded control: 100% versus 38% (p < 0.05). Patent pericyte-seeded
TEVGs revealed extensive tissue remodeling with collagen and elastin present. The remodeled
tissue consisted of multiple layers of α-smooth muscle actin- and calponin-positive cells, and a
von Willebrand factor-positive monolayer in the lumen. These results demonstrate the feasibility
of a pericyte-based TEVG and suggest that the pericytes play a role in maintaining patency of the
TEVG as an arterial conduit.
© 2010 Elsevier Ltd. All rights reserved.
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Introduction
Cardiovascular disease accounts for 1 in every 2.8 deaths in the United States and costs
approximately $475 billion in 2009 [1]. 56% of these deaths come from diseases of
peripheral and coronary arteries, the latter resulting in 500,000 coronary artery bypass grafts
(CABG) each year [1]. Together with CABG, lower limb revascularization and
arteriovenous access grafts for hemodialysis account for more than 1 million vascular graft
implantations per year [2]. Although autologous grafts are the gold standard for bypass
procedures, they are limited by availability. Current synthetic grafts are not suitable for
small-diameter (ID<6mm) vascular applications due to the acute thrombosis [3–5]. While a
tissue-engineered vascular graft (TEVG), constructed by incorporating cells within a
biodegradable scaffold, seems to be a possible solution to this challenge [6–8], its success
greatly relies on an appropriate cell source and an efficient cellular delivery and carrier
system.
Mesenchymal stem cells (MSCs) exhibiting multipotentiality and self-renewal capabilities
could overcome the limitations of slow growth rate and phenotype switching with
terminally-differentiated vascular cells during in vitro culture [9,10]. Utilization of stem
cells from a human source represents a crucial step toward clinical translation of autologous
TEVGs. Human adult MSCs such as bone marrow stem cells [11,12], adipose-derived stem
cells [13] and endothelial progenitor cells [14] have been shown to have potential in TEVG
applications. Recently, the perivascular origin of the MSCs has been shown [15–17].
Pericytes, which closely encircle endothelial cells in capillaries and microvessels [18], have
been shown to be precursors of MSCs [15–17]. Their relative availability from any tissues
with capillary support such as muscle and fat, as well as their multipotentiality, make
pericytes a promising cell source for TEVG applications. Although differentiation toward
myogenic, osteogenic, chondrogenic and adipogenic cell lineages has been demonstrated for
pericytes [15,17], vasculogenic potential of pericytes remains unknown. To our knowledge,
this is the first report on the use of pericytes for TEVG applications.
For those approaches that rely on cell seeding of a scaffold prior to implantation of the
TEVG, few if any utilize a highly-efficient bulk-seeding process to achieve densely and
uniformly distributed cells. The traditional approaches have relied on static cell culture
techniques via pipetting the cell suspension onto the scaffold, which is associated with cell
loss and uneven cell distribution [19–21]. In order to maximize the utilization of donor cells,
we have developed a rotational vacuum seeding device that can efficiently incorporate a
large amount of cells in a short period of time with an even distribution throughout the
thickness [22,23]. The first goal of this study was to rapidly, densely and efficiently
incorporate human pericytes (hPs) into a biodegradable and elastomeric scaffold and
evaluate their subsequent behavior.
Autologous or allogeneic models are typically used to evaluate the performance of animal
stem cell-based TEVGs. For example, TEVGs constructed from sheep endothelial
progenitor cells were implanted as a carotid interposition graft in the same animal [24]. In
another study, autologous bone marrow cell-seeded scaffolds were implanted to replace the
inferior vena cava in dogs [25]. In one of our previous studies, biodegradable scaffolds
seeded with allogeneic rat muscle derived stem cells were used as infrarenal aortic
interposition grafts [26]. Although these studies showed improved patency for cellularized
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TEVGs compared to their acellular counterparts, the outcome of an animal cell-based model
holds minimal relevance for human cell-based TEVGs. Therefore, the second goal of this
study was to assess the performance of the hP-seeded scaffold as an aortic interposition
TEVG in a xenogeneic rat model.
Methods
Fabrication and Characterization of ES-TIPS PEUU scaffolds
Bi-layered, elastomeric and tubular scaffolds (1.3 mm inner diameter) with an inner porous
layer and an external fibrous layer were fabricated from poly(ester-urethane)urea (PEUU).
PEUU was synthesized from polycaprolactone diol and 1,4-diisocyanatobutane with a
putrescine chain extender [27]. The inner PEUU tubular scaffolds were fabricated by
thermally induced phase separation (TIPS) method [28]. Subsequently, PEUU nanofibers
were directly deposited on the external surface of TIPS tubular scaffolds by electrospinning
(ES) to obtain ES-TIPS bi-layered scaffolds [2].
The morphology of ES-TIPS PEUU scaffolds was assessed under scanning electron
microscopy (SEM, JSM-6330F, JEOL, Japan) after platinum coating. The porous structure
of the scaffold was imaged using micro-computed tomography (micro-CT, VivaCT40,
SCANCO Medical, Brüttisellen, Switzerland). Scan settings were E=45 kVp, I=177 μA,
integration time of 300 ms with 3× frame averaging, 10 μm isotropic voxel resolution, and a
scan distance of 2.15 mm. Planar slice images were reconstructed from the isotropic slice
data, and compiled to generate a 3-D image using a low threshold value.
Static compliance was calculated from pressure-diameter data collected via a pressure
transducer (Model TJE, Honeywell-Sensotec Co., Columbus, OH) and He-Ne laster
micrometer (Beta LaserMike, Dayton, OH) as previously described [2]. Tensile tests were
carried out to measure the ultimate tensile stress (UTS) of the scaffold in the circumferential
direction using an Instron 5543A testing machine (Norwood MA) and ring specimens,
following a similar experimental protocol as previously reported [29]. Burst pressure was
estimated from UTS as reported previously [23,30] by rearranging the law of Laplace (i.e.
burst pressure= material yield stress × thickness/radius).
Human Pericyte (hP) Isolation and Culture
The use of hPs was in compliance with the Institutional Review Board at the University of
Pittsburgh. Pericytes derived from human skeletal muscle were isolated and cultured as
previously described [31,32]. Briefly, skeletal muscle was carefully separated from fat and
macro vasculature then minced into small pieces. The muscle was then incubated for 45 min
at 37 °C in medium containing DMEM high glucose (Gibco), 20% FBS (Gibco), 1%
Penicillin-Streptomycin (PS) (Gibco) and complemented by 0.5 mg/ml of each collagenases
type I, II, and IV. The resulting cell suspension was filtered to eliminate all debris. After
rinsing, cells were FACS-sorted according to positive expression for CD146, NG2 (a
proteoglycan associated with pericytes during vascular morphogenesis) and PDGF-Rβ, and
to the absence of hematopoietic (CD45), endothelial (CD34), and myogenic (CD56) cell
markers. The dead cells were excluded by FACS via propidium iodure staining. Sorted
pericytes were seeded at 2×104 cells/cm2 in endothelial cell growth medium 2 (EGM-2,
Cambrex Bioscience) and cultured at 37 °C for 2 weeks in plates coated with 0.2 % gelatin
(Calbiochem). Pericytes were trypsinized once a week and cultured at 1:3 dilution (from
passage 1 to 5) then at 1:10 (after passage 5). Except for the first passage, all pericytes were
cultured in DMEM/FBS/PS proliferation medium in uncoated flasks to maintain their
original phenotype. Pericytes between passages 9 and 11 were used for all experiments.
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Incorporation of Cells into the Scaffolds
The hP suspension was seeded into the ES-TIPS PEUU scaffolds via a previously-described
vacuum rotational seeding device [22]. In brief, the scaffold was connected to two coaxial
stainless steel tees inside an airtight chamber. The chamber was connected to house vacuum
to maintain a negative and constant pressure (−130 mmHg), which induced transmural flow
of the cell suspension across the scaffold. A syringe pump infused the cell suspension
(1×106 cells/mL) at 2.5 mL/min into the manually rotating scaffold to reach 3×106 cells per
scaffold within less than 2 min, resulting in a scaffold with uniformly distributed cells.
Seeded scaffolds were immediately put into static culture for 3 hours, which is sufficient for
cellular attachment [23]. Scaffolds were then transferred to a spinner flask with 200 mL
medium at 15 rpm stirring for 2 days of culture, after which it was implanted into the rat.
Scaffolds were observed under SEM immediately after seeding. The seeded scaffolds after 2
days’ dynamic culture were further assessed for histology (H&E), cellular distribution (F-
actin and nuclear staining), and attachment (SEM). For F-actin staining, cryosections were
permeabilized (0.1 % Triton) for 30 min, blocked (2 % BSA) for 30 min and then incubated
with Alexa 488-conjugated phalloidin (1:500, Sigma) for 1 hour.
Implantation of the hP-Seeded Scaffolds into the Rat Model
All rat studies were conducted in compliance with the Institutional Animal Care and Use
Committee of the University of Pittsburgh. hP-seeded scaffolds (n=7) and unseeded
scaffolds (n=8) were implanted end-to-end into the abdominal aorta of female Lewis rats
(200–300 g, Charles River, PA) as previously described [26]. Briefly, rats were anesthetized
with isofluorane and ketamine. Before skin incision, one dose of cefuroxime (100 mg/kg) as
antibiotic was administered intramuscularly for prophylaxis of surgical infections. The skin
of the anterior abdominal wall was aseptically prepped with povidone-iodine solution. A
midline laparotomy incision was made and the abdominal aorta exposed. Microclamps were
applied to the infrarenal aorta and both common iliac arteries. An interposition aortic hP-
seeded scaffold was sutured to replace the native aorta in an end-to-end anastomotic pattern
with 10.0 prolene. After the scaffold was anastomosed, the clamps were released and
patency of the scaffold verified by direct observation. The muscle layer and skin were then
closed with 3-0 polyglactin absorbable suture. The rats were observed in the surgical suite
until fully recovered from the anesthesia, then returned to the housing area. The first 3 days
after surgery, buprenorphine (0.5 mg/kg) and cefuroxime (100 mg/kg) were administered
intramuscularly. Antiplatelet therapy was started after the surgery with aspirin and
dipyridamole. At the end of 8 weeks, the rats were anesthetized with 5% isofluorane
followed by lethal intracardiac injection of heparin/KCl (40 IU of heparin in 5 ml of KCl)
Patency Assessment
Assessment of patency at the end of the 8 week implant duration was performed via
angiography. Briefly, rats were euthanized and the thoracic descending arteries were
immediately exposed and cannulated with a 22G Angiocath (BD, Sandy, UT). Rats were
then put inside a dynamic angiography system (OEC 9800 Plus, GE Healthcare, Piscataway,
NJ). Iodine contrast medium (Renografin-60, Bracco Diagnostics, Princeton, NJ) was
manually infused through the Angiocath and the angiogram was recorded for patency
verification.
Gross Pathology
After angiography, TEVGs were explanted along with a small length of the host aorta at
both ends and placed in saline. To assess gross pathology, the explanted TEVGs were
observed under a dissecting stereo microscope (SMZ660, Nikon Instruments Inc., Melville,
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NY). TEVGs were subsequently cut into several short segments for the various endpoint
studies as described below.
SEM Analysis
To further evaluate the morphology of the luminal surface, separate segments of TEVGs
were cut along the longitudinal direction, laid flat, fixed in 2.5% glutaraldehyde solution for
30 min and then subjected to serial dehydration in ethanol. After platinum coating, the
luminal morphology of the TEVGs was observed under SEM (JSM-6330F, JEOL Japan).
Histology and Morphometric Analysis
Separated segments of TEVGs and the native rat aorta were fixed in 4% paraformaldehyde,
washed in PBS and then immersed into 30% sucrose solution overnight at 4 °C before
paraffin embedding and sectioning. Hematoxylin & eosin (H&E), Masson’s trichrome stain
and Verhoeff-van Gieson stain were performed following standard histological protocols.
Histological slides were imaged under bright field (Eclipse E800, Nikon Instruments Inc.,
Melville, NY) provided with a digital color CCD camera (Model 2.3.1, Diagnostic
Instruments Inc., Sterling Heights, MI).
Morphometric analysis was carried out for pre-implanted scaffolds (n=9) and explanted hP-
seeded TEVGs (n=7) but not for unseeded control explants as most of them were obstructed.
For each TEVG or scaffold, one 8 μm section of Masson’s trichrome image was taken under
epifluorescent microscope (Nikon Eclipse E800) at the magnification of 4×. Images were
stitched using ImageJ software (National Institutes of Health, MD) to yield an entire cross-
section. Three measurements were taken for each scaffold and then averaged inner (Di) and
outer diameters (Do) were calculated from the luminal (Ai) and total area (Ao) respectively.
The total wall thickness (tT) was calculated as . Due to the distinct edge between the
remodeled tissue and remaining TIPS layer in the histology image, the area enclosed by the
edge of remodeled tissue was measured (Are) and corresponding diameter (Dre) calculated.
Then thickness of the remodeled tissue (tre) was calculated as . The area ratio of
remodeled tissue, reflecting the degree of scaffold remodeling, was defined as the
percentage of total wall area occupied by the remodeled tissue calculated as
.
Imunohistochemistry
Cryosections of the TEVGs and native rat aorta were permeabilized in 0.1 % Triton for 30
min and then blocked in 2% BSA for another 30 min. The cryosections were then incubated
for 1 hour at room temperature with mouse anti-human primary antibodies to α-smooth
muscle actin (SMA, 1:500, Sigma), h1-calponin (CALP, 1:200, Dako), and myosin heavy
chain (MHC, 1:400, Abcam) to detect SMCs, and with rabbit anti-human von Willebrand
factor (vWF, 1:100, Dako) to detect endothelial cells (ECs). After washing, a mixture of
Alexa 488-labeled donkey-anti rabbit and Cy3-labeled donkey-anti mouse IgG was added
and incubated for another 1 hour at room temperature. After counterstaining in DAPI and
mounting in gelvatol, slides were observed under epifluorescence (Nikon Eclipse E800).
Fluorescent in Situ Hybridization (FISH)
Human-specific pan-centromeric and chromosome 12 probes were used to study the
engraftment of hPs in explanted TEVGs. The probes were hybridized onto the cryosections
of the hP-seeded TEVGs and human muscle fibers (positive control). In brief, sections were
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serially dehydrated in ethanol solutions and air dried. A direct rhodamine-labeled
fluorescent all-human centromere satellite probe (Qbiogene/MP Biomedicals, Solon, Ohio)
or biotin-conjugated human chromosome 12 probe (ID LABS INC, London, ON, Canada)
was added onto the sections following the manufacturer’s protocols. Sections were covered
by size-matched plastic coverslips, sealed with rubber cement (Elmer’s) to prevent probe
evaporation then co-denatured for 5 min at 75 °C. Sections were then incubated in a humid
chamber overnight at 37 °C for the hybridization of the probes. Post-hybridization washes
for the centromere probe were performed first in PBS at room temperature, and then in 0.5%
SSC with 0.1% SDS for 5 min at 65 °C, followed again by a PBS wash. Post-hybridization
washes for the chromosome 12 probe were performed first in 2×SSC with 0.1% Igepal
(Sigma), followed by 0.4×SSC with 0.3% Igepal for 2 min at 73 °C, and then in 2×SSC with
0.1% Igepal for 5 min at room temperature. Cy3-conjugated avidin was used to visualize the
chromosome 12 probe. Nuclei were counterstained with DAPI (1:2000, Molecular Probes).
The slides were observed under epifluorescence (Nikon Eclipse E800).
Statistical Analysis
All quantitative values are averaged and expressed as mean ± standard deviation. Student’s
t-test (two-sample unequal variance) was carried out for morphometric analysis. Fisher’s
exact test for nonparametric variables was used to compare patency rate between the seeded
and unseeded TEVGs. P values < 0.05 were considered significant.
Results
ES-TIPS PEUU Scaffold Characterization
Under both SEM (Fig. 1) and micro-CT (Fig. 2), the ES-TIPS PEUU scaffold displayed a
bi-layered structure: i.e. a thick, high-porosity, internal layer, and a thin, dense, fibrous,
external layer. The TIPS layer thickness was approximately 400 μm with a pore size of
approximately 50 μm. The ES layer thickness was approximately 70 μm with a pore size of
approximately 5 μm. The diameter of the ES nanofibers ranges between 500–900 nm.
The ES-TIPS PEUU scaffold had a compliance value of 2.4 ± 1.1%/100 mmHg (n=7),
which is lower than that of the native rat aorta (12.1 ± 1.7%/100 mmHg) and close to that of
the native rat vena cava (4.9 ± 0.8 %/100 mmHg). The measured UTS of the scaffold was
0.8 ± 0.2 MPa (n=6). Burst pressure was estimated to be 4462 ± 1201 mmHg (n=6).
In Vitro hP Seeding and Culture
The open and interconnected pores of the TIPS layer were occupied by cells after seeding
(Fig. 3). The seeding efficiency was above 90%. While most cells were still rounded up
(Fig. 3C), some cells were spread on the surfaces of the pores (Fig. 3D).
Following 2 days of dynamic culture in the spinner flask, hPs populated the whole TIPS
layer of the scaffolds, with a uniform circumferential and radial distribution (Fig. 4). Under
SEM observation, hPs were found to completely fill some pores (Fig. 4B). hPs maintained
their original phenotype of expressing α-SMA, CD 146 and failing to express CD34 and
other EC markers after the dynamic culture (data not shown).
In Vivo Implantation
All scaffolds showed good suturability and pliability which allowed for effective end-to-end
anastomosis. The angiograms performed to evaluate the patency rate showed that all 7
(100%) hP-seeded TEVGs (Fig. 5A) but only 3 out of 8 (38%) unseeded TEVGs (Fig. 5E)
were patent while the rest were obstructed. There was a significant difference in patency rate
between the two groups (p=0.026). All patent hP-seeded TEVGs displayed a tissue-like
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appearance with clear remodeling of the scaffold and without visible signs of infection or
scar tissue formation (Fig. 5B–5D). The lumen of the patent TEVGs was smooth and shiny
without thrombosis formation (Fig. 5B). Patent TEVGs also exhibited size matching with
the native aorta at the anastomosis sites (Fig. 5C). Obstructed unseeded controls showed
overgrowth of tissue in the lumen, suggestive of intimal hyperplasia (Fig. 5F and 5H).
SEM analysis of the luminal surface of the patent TEVGs revealed a smooth transition from
the native aorta to the TEVGs (Fig. 6B) and suggested coverage of an endothelial-like
confluent cells (Fig. 6C). The unseeded controls showed platelet aggregation on the luminal
surface (Fig. 6D).
Histological analysis demonstrated tissue remodeling in the TIPS layer enriched with both
collagen and elastin (Fig. 7A–7F). The ES layer appeared intact without cell infiltration
(Fig. 7D–7F). Similar histology results were observed in the native rat aorta (Fig. 7J–7L).
As expected, the unseeded controls displayed obstructed lumen (Fig. 7G–7I).
Morphometric analysis of the patent hP-seeded TEVGs showed a significantly increased
inner diameter (Di) and outer diameter (Do) (P < 0.05) but similar wall thickness (tT)
compared with the pre-implanted scaffolds (Table 1).
Immunohistochemical analysis showed that the remodeled tissue noticed in Fig. 7A–7F
consisted of multiple layers of α-SMA- and h1-calponin-positive cells, suggesting the
contractile SMC phenotype, and a monolayer of vWF-positive cells, suggesting ECs on the
luminal surface (Fig. 8A–8C). Similar cellular compositions were observed in the native rat
aorta (Fig. 8D–8F), although MHC-positive cells were not found in the TEVGs, suggesting
the regenerated SMCs were not of a fully-contractile phenotype at 8 weeks. It is possible
that with longer implantation duration, SMCs might switch to more mature contractile
phenotype when exposed to continuous cyclic stretching caused by systemic circulation.
None of these vascular markers were observed in the unseeded controls (data not shown).
Fluorescent in situ hybridization (FISH) results showed red signal co-localized with blue
nuclei in the positive control (human muscle sections) for both human-specific probes (Fig.
9A and 9C), indicating the efficiency of probe hybridization to human nuclei was very high.
However, almost no positive staining co-localized with nuclei was visualized on the
explanted hP-seeded TEVG (Fig. 9B and 9D), suggesting a scarcity of human cells and
presence of host rat cells.
Discussion
In this study, we have shown that bi-layered PEUU scaffold efficiently seeded with human
pericytes, dynamically cultured for 2 days, and implanted in vivo remodeled into a patent
small diameter arterial graft. The hP-seeded TEVGs showed a significantly higher patency
rate compared with the unseeded counterparts, suggesting that pericytes play a role in
maintaining patency of the TEVGs.
Generating TEVGs from human cells represents a critical step towards clinical translation of
vascular tissue engineering. Niklason et al., fabricated hTEVGs using genetically-modified
terminally-differentiated SMCs and ECs with telomerase expression isolated from elderly
patients to overcome the limited replicative capacity of adult somatic cells [33]. McAllister
et al., also reported clinical studies of implanting autologous human TEVGs engineered
from human skin fibroblasts and venous endothelial cells as arteriovenous shunts [34].
Although both approaches represent a breakthrough, the use of terminally-differentiated
cells results in a long fabrication time and lack of off-the-shelf capability of TEVG, which
might be overcome by the use of human multipotent stem cells. We have shown here that
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tubular biodegradable scaffolds seeded quickly and efficiently with hPs and pre-cultured for
2 days resulted in SMC- and EC- populated conduits in vivo. These results suggest that
pericytes and other MSCs might be used as an alternative to terminally-differentiated
vascular cells for TEVG application.
Although most reports of xenogeneic implantation use either immune-suppressed animals or
immunodeficient rodents (i.e., SCID mice or nude rat) [11,35,36], we used the immune-
competent Lewis rat. No gross inflammation response to the hP-seeded scaffolds was
observed (Fig. 5–8). One possible explanation for this is that pericytes, as progenitors of
MSCs [16,17], may secrete anti-inflammatory cytokines, resulting in lack of immune
clearance [37]. Immunosuppression by human pericytes is currently under study with
preliminary results supporting this possibility.
The precise role of hPs in TEVG remodeling and functionality is unknown. It is possible
that they provide acute anti-thrombogenicity while modulating the recruitment of host cells
(e.g., from the anastomosis, circulating progenitor cells and/or hematopoietic/immune cells),
which then directly participate in the remodeling process. This possibility is supported by a
report that human bone marrow MSCs seeded on nanofibrous vascular grafts provide anti-
thrombogenicity but majority of the MSCs had short-term (less than 7 days) engraftment in
a rat model [11]. Similarly, it was recently shown that seeded human bone marrow MSCs
enhance the recruitment of host rat monocytes to the TEVGs which participated in the
remodeling, with the seeded cells not detectable within a few days of implantation [21].
The observed dilation of the hP-seeded TEVGs represents a limitation of the work (Table 1).
Since no dilation was observed for the rat stem cell-seeded scaffolds in our previous work
[26], dilation is likely due to distension damage incurred by the scaffold upon in vitro
seeding, or accelerated mechanical degradation of the scaffolds in vivo. hPs are three- to
five-times larger than rat cells. Using the same seeding protocol (i.e., flow rate and driving
pressure of cell suspension infusion) as in our previous rat TEVG studies resulted in high
resistance and dilation of the scaffold during seeding, which may have caused irreversible
structural damage. Even a moderate xenogeneic host-foreign body response could cause
accelerated degradation of the PEUU scaffolds through hydrolysis and macrophage
phagocytosis and result in dilation. Supporting this possibility, we observed that hP-seeded
scaffolds display more profound remodeling than the rat stem cell-seeded counterparts for
the same implantation duration (data not shown). Another limitation of current work is that
the burst pressure was only estimated via a simplified analytical expression (Laplace) due to
the small size of the scaffolds, which might be overestimated by over 50% according to the
report from Cytograft® [30].
Conclusions
A biodegradable, tubular scaffold densely and uniformly seeded with human pericytes, then
cultured for 2 days in a spinner flask, appears to be a promising new, small diameter tissue
engineered vascular graft. After implantation, pericyte-seeded TEVGs showed a higher
patency rate than the unseeded control. The pericytes play a key, yet unknown role in
remodeling the scaffold into a patent TEVG demonstrating tissue-like appearance. Future
work is needed in order to perform more rigorous engraftment studies, functional tests,
longer-term implantation, and cell tracking along the implantation duration.
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Fig. 1.
Representative SEM micrographs of the ES-TIPS PEUU scaffold (ID 1.3 mm). (A) Whole
cross-section; (B) higher magnification of the close-up in (A); (C) higher magnification of
the close-up in (B), showing adherence between the ES and TIPS layer; (D) outer surface of
the ES layer; (E) cross-section of the ES layer; (F) cross-section of the TIPS layer; (G) inner
surface of the TIPS layer.
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Fig. 2.
Representative micro-CT images of the ES-TIPS PEUU scaffold. Cross-section in (A) radial
plane and (B) longitudinal plane.
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Fig. 3.
Representative SEM micrographs of a thin-section (thickness: 10 μm) of the ES-TIPS PEUU
scaffold (A and B) before and (C and D) after cell seeding. (A) Whole cross-section; (B)
higher magnification of the close-up in (A), showing TIPS layer before cell seeding; (C)
TIPS layers after cell seeding; (D) higher magnification of the close-up in (C).
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Fig. 4.
Characterizations of the pre-implanted hP-seeded ES-TIPS PEUU scaffolds after dynamic
culture. (A) H&E staining; (B) SEM (arrows=cells); (C) F-actin staining (red=scaffold;
blue=nuclei; green=F-actin), and (D) nuclear staining (red= scaffold; blue=nuclei). “L”
indicates lumen.
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Fig. 5.
Representative angiographic and gross pathology images of the (A-D) hP-seeded TEVG and
(E-H) unseeded control. (A and E) Angiographic images (arrow=implant); (B and F)
macroscopic images of the lumen, (C and G) entire length, and (D and H) whole cross-
section. Arrows in (C) indicate anastomosis marked by suture lines.
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Fig. 6.
Representative SEM micrographs of the (A-C) hP-seeded TEVG and (D) unseeded control.
(A) Luminal surface of the hP-seeded TEVG with adjacent rat aorta; (B) higher
magnification of the anastomosis site between the rat aorta and the hP-seeded TEVG; (C)
higher magnification of the luminal surface of the hP-seeded TEVG; (D) luminal surface of
the unseeded control, showing the platelet aggregation. Anastomosis is manually depicted in
(A and B).
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Fig. 7.
Representative histological images of the (A-F) hP-seeded TEVG, (G-I) unseeded control,
and (J-L) native rat aorta. (A, D, G and J) H&E, (B, E, H and K) Masson’s trichrome, and
(C, F, I and L) Verhoeff-van Gieson staining. (D-F) Higher magnification of (A-C). Arrows
in (D-F) indicate the thickness of the remodeled tissue layer, while “ES” indicates the ES
layer. The remaining PEUU material was unspecifically stained in black by Verhoeff-van
Gieson stain in (F and I). Magnification for (A-C and G-I): ×4, (D-F): ×40, (J-L): ×20.
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Fig. 8.
Representative immunohistochemistry images of the (A-C) hP-seeded TEVG and (D-F)
native rat aorta. (A and D) α-SMA, (B and E) h1-calponin, and (C and F) myosin heavy
chain (MHC) double-stained with von Willibrand factor (vWF) (red=SMA/calponin/MHC;
green=vWF; blue=nuclei). Arrows indicate lumen. ES layer is indicated in (A-C), showing
no cell infiltration in the ES layer.
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Fig. 9.
Representative fluorescent in situ hybridization (FISH) images for engraftment study. (A
and B) Human-specific chromosome 12 probe, (C and D) human-specific pan-centromeric
probe (red=signal; blue=nuclei). (A and C) Human muscle fiber acting as a positive control
and (B and D) explanted hP-seeded TEVG. Magnified images are shown in the insets.
Magnification for (A-D): ×20; insets in (A and B): ×60; insets in (C and D): ×40.
Fluorescent images and bright field images are overlaid in (B, C, and D).
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Table 1
Morphometric analysis results showing the inner diameter (Di), outer diameter (Do), total wall thickness (tT),
remodeled tissue thickness (tre), and area ratio of the remodeled tissue from the explanted hP-seeded TEVGs
(n=7) and pre-implanted scaffolds (n=9).
Explanted TEVGs (n=7) Pre-Implanted Scaffolds (n=9)
Inner Diameter (Di) (mm) 1.89 ± 0.57 * 0.95 ± 0.08
Outer Diameter (Do) (mm) 2.73 ± 0.53 * 1.85 ± 0.15
Total Wall Thickness (tT) (μm) 420 ± 144 453 ± 74
Remodeled Tissue Thickness (tre) (μm) 226 ± 91 n/a
Area Ratio of Remodeled Tissue 50% ± 17% n/a
The asterisk (*) indicates a statistically significant difference from the pre-implanted scaffolds (p < 0.05).
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